Medinotec Inc.
MDNC · Healthcare · FY2026 filings · · not refreshed in 35 days · Narrow moat ·
On the watchlist
The five investor questions
Fewer than two aligned fiscal years of revenue and diluted EPS are available; the filing history does not contain a measurable trend.
Median gross margin 52.8% over 4y, very stable.
Median ROIC 124.8%, above the 12% hurdle in 100% of years.
Net debt/EBITDA n/ax, interest coverage 12x.
Owner earnings changed trend unclear over up to the ten most recent annual observations.
The businessTrend component abstained: Fewer than two aligned fiscal years of revenue and diluted EPS are available; the filing history does not contain a measurable trend. The other four 20% weights were renormalized over the scored 80%.
Price vs. value if growth stopped today
A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.
- $279902
- $0.26
- $0.26
- Unavailable — no recent price
- No price data
This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.
Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.
Score records captured Jul 26, 2026.
Exactly which 50 companies?
FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY
Missing a usable price or zero-growth estimate: ANF, BKNG.
Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
6 years of fundamentals
The business, in plain English
Medinotec Inc. booked $9.7M of revenue in FY2026 in the Healthcare sector and kept 52.7% of it as gross profit — a solid-margin business by that measure. After every other cost, 8.2% of each revenue dollar reached the bottom line.
MDNC's latest filed year, FY2026, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Gaps in a line mean that item isn’t in MDNC’s filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Visual explainers
The filing-backed explainer service is temporarily unavailable, so no partial or guessed chart is shown.
Moat Score history
Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.
Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars
- Normalizer upgraded unstamped (version unknown)tomoat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
- Methodology upgraded moat-index@2.0.0tomoat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.
Insider activity
Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”
These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.
This machine-readable surface covers SEC ownership filings from 2003; it does not represent earlier paper-era records.
No reported Form 4 transactions were found in the complete checked issuer window for MDNC, –. The totals and cluster result below are arithmetic over that certified window.
- $0 P purchases minus S sales only, Aug 31, 2025–Aug 31, 2026.
- 0 P / 0 S Only P and S are included; awards, gifts, exercises, withholding, and other mechanics are excluded.
- No Requires at least 3 distinct insiders with P purchases.
Transaction-code histogram
Supporting event counts for the same certified window, Aug 31, 2025–Aug 31, 2026.
- P
- 0
- S
- 0
- A
- 0
- F
- 0
- M
- 0
- G
- 0
- C
- 0
- J
- 0
- W
- 0
Retrieved .
Track record
How Medinotec Inc.’s moat rated in each of the years we can reconstruct from its filings — scored only on what was knowable at the time — and what its price and returns did afterward. The score never saw a price; the two are joined only in hindsight, for education, not as a signal.
How to read this: each dot is what the engine would have scored MDNC on that December 31; the line below is its total-return price path (dividends reinvested) in the years since.
Two tracks, one timeline: the score has its own 0–100 scale (top), the price its own 100-based scale (bottom) — never a shared axis. The indexed price path isn't available for this company yet; gaps in the score line are years with no reconstructed rating (see the table for why). The Table view carries every value.
What followed, in the years it rated Wide
In the reconstructed history shown, MDNC did not rate Wide-moat in any year, so there is no wide-moat track record to report. That absence is itself the honest answer — we don’t manufacture a comparison where the rating never earned one.
Healthcare context
#73 of 710 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #71FTLF FITLIFE BRANDS, INC.65.7 out of 100, Narrow moatNarrow moat
- #72UHS UNIVERSAL HEALTH SERVICES, INC.65.6 out of 100, Narrow moatNarrow moat
- #74BSX BOSTON SCIENTIFIC CORP65.3 out of 100, Narrow moatNarrow moat
- #75BBNX BETA BIONICS, INC.65.3 out of 100, Narrow moatNarrow moat
Compare MDNC with its nearest peers →All Healthcare companies on the Index →
Common questions about MDNC
- Does Medinotec Inc. have an economic moat?
- Based on its FY2026 SEC filings, the Moat Index scores Medinotec Inc. (MDNC) 65.4 out of 100 — a Narrow moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend not measurable from the filings, pricing power 84, returns on capital 100, balance-sheet safety 54, capital allocation 24.
- How has MDNC's Moat Score changed over time?
- The record logs 12 readings since Jul 18, 2026; the latest reads 65.4 out of 100 (narrow moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.